Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

At the moment, Infisical does not synchronize nested secret directories when setting up a sync integration (e.g. with Vault). This means that for the same connection, it is required to create a ...

axiom P : Nat → Prop axiom P.intro : P n inductive AckFuel : (n m : Nat) → Type where | step1 : AckFuel 0 m | step2 : AckFuel n 1 → AckFuel (n + 1) 0 | step3 : (∀ m', P m' → AckFuel n m') → AckFuel (n ...

You could say Josh Calder ’87 has a thing for islands: As of this writing, he’s been to 639 of them, cataloged in documents, photos, spreadsheets, and maps. Islands have enchanted Calder—a Washington, ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Before market open, Recursion disclosed in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC) that it was taking a series of measures to streamline its operations.